Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

ASCENDIS PHARMA BONE DISEASES A/S Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   29.6% 28.5% 26.8% 27.2% 19.1% 30.3% 20.5% 20.5%   Credit score (0-100)   2 2 2 1 6 1 5 5   Credit rating   C B B B B C B B   Credit limit (kEUR)   -0.0 -0.0 -0.0 -0.0 -0.0 -0.0 -0.0 -0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kEUR)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   -27,476 -38,797 -57,982 -66,598 -112 -34.0 0.0 0.0   EBITDA   -27,593 -38,913 -58,098 -66,715 -112 -108 0.0 0.0   EBIT   -27,593 -38,913 -58,098 -66,715 -112 -108 0.0 0.0   Pre-tax profit (PTP)   -29,136.0 -41,382.0 -61,966.4 -72,299.5 -119.1 -139.6 0.0 0.0   Net earnings   -28,817.7 -41,299.8 -61,825.3 -72,197.5 -119.0 -139.1 0.0 0.0   Pre-tax profit without non-rec. items   -29,136 -41,382 -61,966 -72,299 -119 -140 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kEUR)  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Tangible assets total   100 72.1 44.2 16.3 0.0 0.0 0.0 0.0   Shareholders equity total   -73,847 -115,147 -176,972 -249,170 -368 -507 -507 -507   Interest-bearing liabilities   85,190 128,547 195,305 267,705 408 522 507 507   Balance sheet total (assets)   14,856 18,140 18,339 18,541 39.6 15.4 0.0 0.0   Net Debt   85,189 125,372 195,303 267,659 382 522 507 507     See the entire balance sheet 1000.0 Volume  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   -27,476 -38,797 -57,982 -66,598 -112 -34.0 0.0 0.0   Gross profit growth   -45.5% -41.2% -49.4% -14.9% 99.8% 69.7% 0.0% 0.0%   Employees   0 0 0 0 0 0 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   14,856 18,140 18,339 18,541 40 15 0 0   Balance sheet change%   10.3% 22.1% 1.1% 1.1% -99.8% -61.0% -100.0% 0.0%   Added value   -27,592.8 -38,913.3 -58,098.5 -66,714.8 -112.4 -108.5 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -114 -28 -28 -28 -16 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -4.0 -5.0 -5.0 -5.0 -5.0 -5.0 0.0 0.0   1000.0 Profitability  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   100.4% 100.3% 100.2% 100.2% 100.0% 318.9% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   -37.5% -35.1% -35.4% -28.8% -0.1% -23.1% 0.0% 0.0%   ROI %   -40.8% -36.4% -35.9% -28.8% -0.1% -23.1% 0.0% 0.0%   ROE %   -203.5% -250.3% -339.0% -391.5% -1.3% -505.4% 0.0% 0.0%   1000.0 Solidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Equity ratio %   -83.3% -86.4% -90.6% -93.1% -90.3% -97.0% -100.0% -100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -308.7% -322.2% -336.2% -401.2% -340.2% -481.1% 0.0% 0.0%   Gearing %   -115.4% -111.6% -110.4% -107.4% -110.8% -102.9% -100.0% -100.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   2.3% 2.3% 2.4% 2.4% 0.0% 6.9% 0.0% 0.0%   1000.0 Liquidity  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Quick Ratio   1.1 1.5 719.7 753.9 3,649.1 0.4 0.0 0.0   Current Ratio   1.1 1.5 719.7 753.9 3,649.1 0.4 0.0 0.0   Cash and cash equivalent   0.6 3,174.8 2.5 46.1 25.5 0.2 0.0 0.0   1000.0 Capital use efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   361.1 2,445.9 4,223.6 4,454.1 25.5 -2.4 -253.6 -253.6   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024 2024/12 2025e N/A 2026e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 0 0 0   EBIT / employee   0 0 0 0 0 0 0 0   Net earnings / employee   0 0 0 0 0 0 0 0